Karuna Therapeutics, Inc. (KRTX) News

Karuna Therapeutics, Inc. (KRTX)

Today's Latest Price: $98.99 USD

1.19 (-1.19%)

Updated Jul 8 4:00pm

Add KRTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

Filter KRTX News Items

KRTX News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest KRTX News From Around the Web

Below are the latest news stories about Karuna Therapeutics Inc that investors may wish to consider to help them evaluate KRTX as an investment opportunity.

Hedge Funds Keep Buying Karuna Therapeutics, Inc. (KRTX)

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

Yahoo | June 28, 2020

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Insiders Increased Their Holdings

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

Yahoo | June 24, 2020

Karuna to advance lead drug into Phase 3 for psychosis in schizophrenia patients

Fresh off a meeting with the FDA, Karuna Therapeutics (KRTX) will advance lead candidate KarXT into Phase 3 development for the treatment of acute psychosis in patients with schizophrenia.The agency is on board with one successful late-stage study, along with additional safety data and results from previously generated trials, to...

Seeking Alpha | June 23, 2020

Karuna Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with Schizophrenia

Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced next steps in the clinical program evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia following the completion of a successful End-of-Phase 2 meeting with the U.S. Food & Drug Administration (FDA). The outcome of the meeting supports the progression of KarXT into Phase 3 development. The Company remains on track to initiate the Phase 3 program by the end of 2020.

Yahoo | June 23, 2020

Karuna Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna Therapeutics, will participate in a fireside chat at the virtual Goldman Sachs Annual Global Healthcare Conference

Business Wire | June 3, 2020

Karuna Therapeutics to Present Additional Data from the Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia at the American Society of Clinical Psychopharmacology 2020 Annual Meeting

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, announced today that data from the Phase 2 clinical trial evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia will be presented at the American Society of Clinical Psychopharmacology (ASCP)

Business Wire | May 27, 2020

Surging Earnings Estimates Signal Good News for Karuna Therapeutics (KRTX)

Karuna Therapeutics (KRTX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Zacks Investment Research | May 20, 2020

Karuna Therapeutics Reports First Quarter 2020 Financial Results and Provides General Business Update

Karuna Therapeutics, Inc. (Nasdaq: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the pote

Business Wire | May 7, 2020

Karuna Therapeutics Appoints Christopher J. Coughlin to its Board of Directors

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced the appointment of Christopher J. Coughlin to its board of directors. Mr. Coughlin will chair Karuna’s audit committee. “We are thrilled to have Chris join our board,” stated Steve Paul, M.D., chief executiv

Business Wire | April 28, 2020

The Zacks Analyst Blog Highlights: Livongo Health, Karuna Therapeutics, Sprouts Farmers Market, PennyMac Financial Services and Strategic Education

The Zacks Analyst Blog Highlights: Livongo Health, Karuna Therapeutics, Sprouts Farmers Market, PennyMac Financial Services and Strategic Education

Zacks Investment Research | April 27, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6258 seconds.